"The voice for cancer physicians and their patients in Massachusetts."
The U.S. Food and Drug Administration approved selumetinib (Koselugo; AstraZeneca) for neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurocfibromas (PN). Read full press release.
© Copyright. All rights reserved.
Massachusetts Society of Clinical Oncologists
P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: email@example.com